Previous Close | 39.91 |
Open | 39.91 |
Bid | 39.04 x 1300 |
Ask | 39.66 x 1300 |
Day's Range | 39.29 - 40.18 |
52 Week Range | 29.85 - 59.46 |
Volume | |
Avg. Volume | 997,011 |
Market Cap | 5.22B |
Beta (5Y Monthly) | 1.24 |
PE Ratio (TTM) | 23.14 |
EPS (TTM) | 1.71 |
Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 51.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for HALO
On September 19, 2023, Michael Labarre, the Senior Vice President and Chief Technical Officer of Halozyme Therapeutics Inc (NASDAQ:HALO), sold 10,000 shares of the company.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.